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Abstract: Type 1 diabetes (T1D) results from the progressive loss of pancreatic beta cells as a result of
autoimmune destruction. We recently reported that during the natural history of T1D in humans
and the female nonobese diabetic (NOD) mouse model, beta cells acquire a senescence-associated
secretory phenotype (SASP) that is a major driver of disease onset and progression, but the mechanisms
that activate SASP in beta cells were not explored. Here, we show that the SASP in islet cells is
transcriptionally controlled by Bromodomain ExtraTerminal (BET) proteins, including Bromodomain
containing protein 4 (BRD4). A chromatin analysis of key beta cell SASP genes in NOD islets revealed
binding of BRD4 at active regulatory regions. BET protein inhibition in NOD islets diminished not
only the transcriptional activation and secretion of SASP factors, but also the non-cell autonomous
activity. BET protein inhibition also decreased the extent of SASP induction in human islets exposed
to DNA damage. The BET protein inhibitor iBET-762 prevented diabetes in NOD mice and also
attenuated SASP in islet cells in vivo. Taken together, our findings support a crucial role for BET
proteins in the activation of the SASP transcriptional program in islet cells. These studies suggest
avenues for preventing T1D by transcriptional inhibition of SASP.
Keywords: senescence and SASP; beta cells; type 1 diabetes; BET proteins
1. Introduction
Type 1 diabetes (T1D) is a chronic metabolic disease of insulin deficiency caused by an organ-specific
autoimmune disorder that leads to progressive loss of pancreatic beta cells. The conventional model
for T1D pathogenesis posits a loss of peripheral tolerance, resulting in beta cell-specific autoimmunity
of cluster of differentiation 4 positive (CD4+) and CD8+ T cells that carry out beta cell destruction
with support from innate immune cells [1,2]. While T cell-mediated beta cell destruction is indeed
the main driver of the disease, we recently demonstrated that beta cells actively participate in the
process by undergoing DNA damage-induced senescence, upregulation of the pro-survival factor
B cell lymphoma 2 (Bcl-2), and acquiring a senescence-associated secretory phenotype (SASP) [3].
Selective ablation of senescent beta cells with small molecule senolytic compounds targeting Bcl-2
prevented T1D in the nonobese diabetic (NOD) mouse model by halting the autoimmune destruction
process and preserving beta cell mass [3]. These results demonstrate a causal role for SASP beta
cells in the pathogenesis of T1D; however, the mechanisms of SASP activation in beta cells have not
been determined.
SASP is controlled at multiple levels, including the level of chromatin and transcription [4,5].
Genes encoding SASP factors are dramatically upregulated in senescent cells, which generally correlates
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with increased protein level and secretion [6,7]. SASP occurs in the context of persistent DNA damage
response (DDR) signaling and results from extensive chromatin remodeling and activation of regulatory
regions of the genes that encode SASP factors [8–11]. Recent efforts have revealed a growing list of
transcription factors, chromatin architectural proteins, and modifiers that collaborate to orchestrate
the activation of SASP genes, leading to the development of the secretory phenotype. These include
factors such as ATM, macroH2A1, HMGB2, MLL1, BRD4, NF-κB, CEBPβ, Mitf, and PARP-1, and
inhibition or depletion of these factors in senescent cells reduces SASP gene activation and subsequent
protein secretion [5,8–10,12,13]. Activation of SASP genes is also accompanied by changes in chromatin
modifications, including the acquisition of marks associated with active enhancers, such as histone
H3K27 acetylation (H3K27ac) [8]. Because most of the previous studies investigated the chromatin
remodeling and activation of SASP genes in human primary fibroblast lines, it remains unclear whether
some of the same transcription factors and chromatin modifiers are required to activate SASP in other
cell types and in vivo. Owing to the ability of accumulated SASP cells to profoundly alter tissue
microenvironments and disrupt normal processes [14,15], pharmacological approaches to inhibit SASP
at the transcriptional level could prove useful for mitigating the effects of senescent beta cells in T1D.
Here, we show that transcriptional activation of the SASP in islets relies upon epigenetic readers
of histone lysine acetylation the BET proteins, including BRD4. BRD4 was bound to active SASP gene
enhancers marked with H3K27ac in NOD islets. Inhibition of BRD4 chromatin binding with the potent
small molecule BET inhibitor iBET-762 led to diminished SASP gene expression, protein secretion and
SASP paracrine activities from NOD islets. We further show that BET protein transcriptional activity
is required for SASP in human islets undergoing DNA damage. Finally, treatment of NOD mice
with iBET-762 prevented diabetes and attenuated SASP in islets in vivo. Taken together, these results
demonstrate that BET proteins are key transcriptional activators of SASP in islet cells and indicate that
the mechanism of diabetes prevention with BET inhibitors involves attenuation of SASP.
2. Results
2.1. BRD4 Is Required for SASP Gene Activation in NOD Islets
We previously demonstrated the expression of SASP genes in beta cells at 14–16 weeks in
euglycemic NOD mice [3]. To confirm that SASP gene regulatory regions were activated in NOD
islets, we performed chromatin immunoprecipitation (ChIP) for H3K27ac. Female NOD mice were
used throughout our studies because of their higher disease penetrance [16]. We used the dbSUPER
superenhancer database [17] and the VISTA enhancer database (Lawrence Berkeley National Lab) to
identify putative enhancers of SASP genes from different mouse cell types. ChIP analysis revealed
enrichment of H3K27ac within the enhancer of Mmp2 and the promoter/enhancer of Il6 relative to
distal regions in the islets of some euglycemic NOD mice, but not others (Figure 1a), consistent
with the heterogeneity in the extent of beta cell SASP among mice at the same age [3]. Epigenetic
readers of H3K27ac include the BET proteins BRD2, BRD3, and BRD4, which are expressed in most
somatic cell types, but are recruited to regulatory regions to activate transcription. BRD4 is a crucial
activator of SASP gene enhancers in human fibroblasts [8,18]; therefore, we focused on this paralogue.
Immunohistochemistry (IHC) demonstrated the broad expression of BRD4 in beta cells, other non-beta
islet cells, and exocrine acinar cells of eight-week-old euglycemic NOD mice (Figure 1b), in which
SASP beta cells are rare [3], consistent with the notion that BRD4 expression alone does not induce
SASP. To determine whether BRD4 binds to SASP gene regulatory regions in islets, ChIP analysis was
performed on islets pooled from multiple NOD mice at 14 weeks of age. This revealed that BRD4
was specifically enriched at the same regulatory regions of Mmp2 and Il6 that harbored H3K27ac,
and treatment of islets with the potent small molecule BET inhibitor iBET-762 disrupted its binding
at these sites (Figure 1c). To determine whether BRD4 activates SASP genes in specifically in islet
cells, dispersed islets isolated from euglycemic 14-week-old NOD mice were depleted of infiltrated
CD45+ immune cells to enrich for endocrine islet cells and then incubated with iBET-762 (Figure 1d).
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iBET-762-treated islet cell cultures showed reduced expression of specific beta cell SASP genes Mmp2,
Il6, Flnb, and Igfbp4 [3] (Figure 1d). As iBET-762 can affect the chromatin binding of all three BET
paralogues, we also used siRNA knockdown to assess the specific contribution of BRD4. siRNA
knockdown of Brd4 in NOD islets diminished Il6 expression (Figure 1e). Together, these results
implicate BET proteins, and in particular, BRD4, as activators of SASP gene expression in NOD islets.
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chain reaction (qRT-PCR) analysis. qRT-PCR of SASP genes Mmp2, Il6, Flnb, and Igfbp4 show the 
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Figure 1. BET protein BRD4 is required for transcriptional activation of senescence-associated secretory
phenotype (SASP) genes in nonobese diabetic (NOD) islets. (a) Chromatin immunoprecipitation and
quantitative polymerase chain reaction (ChIP and qPCR) for H3K27ac at the enhancer of Mmp2 and
promoter of Il6, along with distal negative regions, on islets isolated from two different euglycemic
14-week-old NOD mice (NOD413, NOD414), n = 2 biological replicates per mouse. Female mice are used
throughout our study. The schematic shows the positions of the regions in the ChIP. Immunoglobulin
G (IgG) ChIP was a negative control. Error bars are SD. (b) Representative IHC for BRD4 and insulin
with DAPI on pancreas section from euglycemic NOD mice at eight weeks of age. Scale bar = 20 µm.
(c) ChIP and qPCR for BRD4 at the same regulatory regions of Mmp2 and Il6 shown in (a) on pooled islets
from euglycemic 14-week-old NOD mice cultured for 18 h with vehicle or iBET-762 (n = 2 biological
replicates per group), error bars are SD. IgG ChIP was a negative control. (d) Islets isolated from
14-week-old NOD mice were depleted of CD45+ immune cells to enrich for endocrine islet cells and
then cultured for 24 h with vehicle (Dimethyl Sulfoxide, DMSO) or iBET-762 followed by quantitative
reverse transcription polymerase chain reaction (qRT-PCR) analysis. qRT-PCR of SASP genes Mmp2,
Il6, Flnb, and Igfbp4 show the average relative expression for vehicle (n = 5 biological replicates) or
iBET-762 treated (n = 4 biological replicates) islets cells. Error bars are SD. (e) qRT-PCR for Brd4 and Il6
on 14-week-old NOD islets transfected with non-targeting control or Brd4 siRNAs. Data show average
expression levels in siBrd4 relative to siCtrl from n = 3 independent experiments. Error bars are SD.
For all panels, * p < 0.05, ** p < 0.005, *** p < 0.0005, two-tailed t-tests.
Int. J. Mol. Sci. 2019, 20, 4776 4 of 13
2.2. BET Inhibition Blunts SASP Secretion and Paracrine Activities
Next, we determined whether disrupting BET protein chromatin binding affected SASP protein
secretion. To this end, we cultured NOD islets in iBET-762 or vehicle and collected conditioned media
(CM) for analysis of SASP factors by luminex assay (Figure 2a). Notably, iBET-762-treated islets
showed significantly lower secretion of SASP factors IL-6, Igfbp3, Mmp3, and Mmp12 (Figure 2a).
The beta cell SASP exerts non-cell autonomous effects including the ability to induce senescence-related
changes in immature islet cells and stimulate the chemotaxis of monocytes in vitro [3]. To address
whether iBET-762 treatment affected the paracrine senescence activities of SASP in the CM, we cultured
islets from three-week-old NOD mice with CM from islets depleted of CD45+ cells of vehicle or
iBET-762-treated 14-week-old NOD mice (Figure 2b). While CM from vehicle-treated islets showed
induction of Cdkn1a expression, consistent with paracrine senescence, the iBET-762-treated islet CM
did not (Figure 2b). Finally, we tested whether the CM from iBET-treated NOD islets had effects
on monocyte chemotaxis using the transwell assay (Boyden chamber assay) on the human THP-1
monocyte cell line. Importantly, CM from NOD islet cells cultured with iBET-762 showed diminished
chemotactic activity relative to the vehicle-treated islet CM (Figure 2c), in line with their lower SASP
factor secretion (Figure 2a). These data demonstrate that disruption of BET protein transcriptional
activity in islets leads to decreased SASP secretion and non-cell autonomous activities.
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Figure 2. iBET-762 attenuates SASP secretion and paracrine activities from NOD islets. (a) Islets isolated
from 14-week-old NOD mice were cultured in vehicle or iBET-762 for 24h and the conditioned media
(CM) was collected for luminex assays. Relative quantification of average secretion of SASP factors IL-6,
Igfbp3, Mmp3, and Mmp12 from iBET-762-treated islets versus vehicle-control islets, n = 3 biological
replicates per group. Error bars are SD. * p < 0.05, ** p < 0.005, *** p < 0.0005, two-tailed t-tests. (b) Islets
isolated from 14-week-old NOD mice were depleted of CD45+ cells and cultured in vehicle or iBET-762
for 24 h and the resulting CM was collected used in paracrine senescence induction assays on islets
from three-week-old old NOD mice, where qRT-PCR for Cdkn1a was a readout of paracrine senescence
induction. Regular islet media (not conditioned by islets) was used as a negative control to set the
baseline. Data are average relative expression levels from n = 5 or 6 biological replicates per group,
error bars are SD. ** p < 0.005, one-way analysis of variance (ANOVA). (c) CM was collected from
islets of 14-week-old NOD mice cultured with vehicle or iBET-762 and used in chemotaxis assays on
THP-1 cells. Regular islet media (not conditioned by islets) was used as a negative control to measure
the baseline. Data are chemotaxis fold-change, relative to control, from n = 3 biological replicates per
group. Error bars are SD. ** p < 0.005, one-way ANOVA.
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2.3. BET Proteins Are Required for SASP in Human Islets
We previously showed by IHC that SASP beta cells accumulate in T1D donors as compared with
nondiabetic donors [3]. IHC of BRD4 in age-matched human nondiabetic, autoantibody-positive
(positive for serum beta cell autoantibody, but not diabetic) and T1D donor pancreas sections showed
that it was expressed in the vast majority of INS+ and INS− islet cells and acinar cells in each donor
(Figure 3a), similar to the staining in 8-week-old NOD mice (Figure 1b). The similar expression
patterns in islets of nondiabetic and T1D donors suggest that BRD4 alone is insufficient to induce SASP.
Induction of DNA damage in human islets ex vivo can lead to acquisition of an SASP reminiscent of
the SASP expressed in beta cells of T1D donors [3]. To determine whether BET proteins are recruited to
activate SASP in human islets, we utilized our previous approach for inducing SASP in human islets [3].
Human islets were first treated with bleomycin (bleo) to induce DNA damage or vehicle as a control.
Then, after washout of bleo or vehicle, islets were cultured in the presence of vehicle or iBET-762
and monitored for persistent DDR and SASP development by qRT-PCR and luminex assays six days
later (Figure 3b). Bleo treatment induced sustained expression of CDKN1A relative to the vehicle
control in two different preparations of donor islets (male and female), whereas CDKN2A (INK4A/P16)
was unaffected (Figure 3c), consistent with previous our findings [3]. In contrast, iBET-762 treatment
diminished the expression CDKN1A after bleo (Figure 3c), suggesting a reduction in the extent of
persistent DDR signaling. Furthermore, while bleo-treated islets developed a SASP, as evidenced
by upregulated secretion of SASP factors CXCL1, IL-8, and IGFPB4, iBET-762 treatment after bleo
attenuated the secretion (Figure 3d). Taken together, these data demonstrate that BET proteins are
required for SASP activation in human islets.
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(d) Luminex assay of average protein secretion of SASP factors CXCL1, IL-8, and IGFPB4 from the same
islets as in (c). Each dot represents a biological replicate of islets (n = 6 per group, from the two different
donors shown in (c). Error bars are SD. * p < 0.05, ** p < 0.005, *** p < 0.0005, one-way ANOVA.
2.4. BET Protein Inhibition Diminishes SASP In Vivo
Previous work has shown that inhibition of BET proteins with the earlier generation inhibitor
iBET-151 protects against diabetes in NOD mice [19]. However, the mechanisms of its action on beta
cells were not determined. To investigate this mechanism, we first treated a cohort of 12-week-old
euglycemic NOD mice (n = 10 mice per group) with either vehicle or iBET-762 over a two-week period,
and then monitored random blood glucose levels weekly until 30 weeks of age (Figure 4a). Blood
glucose measurements showed that 60% of vehicle-injected mice developed diabetes by 30 weeks of
age, whereas only 10% of the iBET-762 injected mice developed hyperglycemia by 30 weeks of age
(p = 0.0115, Figure 4a). Histological staining of pancreas sections confirmed that a greater number of
islets was preserved intact in iBET-762-treated mice (Figure 4b), indicating that iBET-762 halted disease
progression, consistent with the previous study using iBET-151 [19].Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 13 
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Figure 4. iBET-762 prevents diabetes and attenuates SASP in vivo. (a) Twelve-week-old NOD mice
(n = 10 per group) were administered vehicle or iBET-762 intraperitoneally (i.p.) for two weeks and
glycemia was monitored up to 30 weeks of age. Diabetes incidence curves show the frequency of
hyperglycemic mice at each time point. Gray shaded area shows treatment window (12–14 weeks of
age). p = 0.0115, log-rank test. (b) Insulits grading in n = 30 islets taken from two euglycemic vehicle
control and two euglycemic iBET-762 mice after the prevention study in (a) at 30 weeks. Error bars
are SD. (c) Recent onset hyperglycemic NOD mice were administered vehicle or iBET-762 i.p. for one
week and then IHC was performed for SASP markers. Representative IHC of SASP factors IL-6 or
Flnb with insulin in pancreas sections from the indicated diabetic mice after treatment. Scale bars =
20 µm. (d) Quantification of IL-6+/Ins+ cells per islet in the hyperglycemic NOD mice treated as in
(a). Each dot represents an islet, where n = 20 islets for a total of 735 beta cells were scored from three
vehicle-treated mice, and n = 16 islets for a total of 891 beta cells were scored from three iBET-762-treated
mice. * p < 0.05, two-tailed t-test.
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We hypothesized that the protective effect of BET protein inhibition resulted at least in part
from its inhibition of SASP. Consistent with this, treatment of recent onset hyperglycemic NOD mice
with iBET-151 also had a beneficial effect on beta cell function [19], which would be expected if this
treatment affects the SASP program. To test whether BET inhibition diminished the SASP in vivo,
recent onset hyperglycemic NOD mice were injected every day for one week with either vehicle or
iBET-762 and pancreas sections were immunostained for SASP markers (Figure 4c). Vehicle-injected
hyperglycemic NOD mice showed a robust expression of IL-6 and Flnb in Ins+ cells and in some Ins−
islet cells (Figure 4c). In contrast, islets from iBET-762-injected hyperglycemic mice showed fewer
cells expressing IL-6 or Flnb (Figure 4c). The frequency of IL-6+/Ins+ (beta) cells per islet was variable
in hyperglycemic mice, similar to our previous observations of SASP heterogeneity in beta cells of
euglycemic NOD mice [3]. Nevertheless, quantifications showed an approximately 50% reduction
in the average frequency of IL-6+ beta cells per islet in iBET-762-treated hyperglycemic mice relative
to vehicle controls (30% in vehicle versus 14% in iBET-762, Figure 4d). Taken together, these results
demonstrate that BET inhibition with iBET-762, which is sufficient to prevent diabetes in NOD mice,
also blunts SASP in vivo.
3. Discussion
Our findings implicate BET proteins as crucial transcriptional activators of SASP in islets cells
of mice and humans. Our findings also indicate that in NOD mice, the protection afforded by BET
inhibitors against diabetes involves attenuation of SASP. However, it is important to recognize that
because BET proteins are also expressed in some immune cell types, where they activate genes for
immune responses, BET inhibitors can also block immune inflammatory responses unrelated to
SASP [18]. In addition, like their predecessor JQ1, second-generation BET inhibitors such as iBET-151
and the more potent derivative iBET-762 affect the chromatin binding of all of the paralogues [20],
and there may be different contributions of BRD2, BRD3, and BRD4 to SASP activation in islets versus
inflammatory responses in immune cells. Regardless, the net-effect of BET inhibition in the NOD model
is remarkably beneficial, perhaps as a result of both diminishing SASP and reducing inflammatory
gene expression in immune cells [19].
Transcriptional inhibition of SASP genes with iBET-762 in NOD islets had a corresponding
downstream effect on SASP factor secretion and paracrine activity. Remarkably, BET inhibition also
affected the extent of persistent DDR and SASP in human islets exposed to DNA damage, revealing a
conservation of this mechanism in human islets. Inhibition of BRD4 in human fibroblasts after the
induction of senescence also inhibits activation of SASP [8], consistent with our findings in human
islets. While we focused on BRD4 in the current study, genetic approaches will be required to delineate
contributions of BRD2 and BRD3 to SASP activation in mouse and human islets.
The mechanism by which BET proteins are recruited to SASP gene regulatory regions in islet
cells remains to be determined. BRD4 was expressed ubiquitously throughout islets and in acinar
cells in NOD mice and humans, indicating that it is not sufficient to drive SASP activation on its own.
BRD4 interacts with NF-κB to facilitate transcriptional activation of SASP genes in fibroblasts [8,21].
Although this pathway may also operate during SASP in islets, there may also be islet cell-specific
transcription factors induced during senescence that recruit BET protein activity. Islet cell-specific
transcription factors that interact with BRD4 would be attractive targets for designing small molecules
to selectively inhibit SASP gene expression. Unlike BET inhibitors, this approach would disentangle
the effects of SASP inhibition in islet cells from the inhibitory effects on inflammatory responses in
immune cells.
Selective targeting of transcriptional and epigenetic regulators such as the BET protein family
using small molecule probes is emerging as a powerful approach to treat a variety of diseases resulting
from their aberrant activity [20]. As BET proteins contribute to the SASP transcriptional program
in human islets, our work suggests that this concept may also be relevant to the prevention and/or
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treatment of T1D in humans. In conclusion, targeted inhibition of the SASP transcriptional program
may provide a new opportunity to develop therapies for T1D.
4. Materials and Methods
4.1. Animal Husbandry and Procedures
All procedures involving mice were performed according to the IACUC standards following
ethics approval by the animal committee at the University of California San Francisco (AN159774-02A,
1 September 2019). Female NOD/ShiLtJ mice (from Jackson Labs) or NOD/MrkTac (from Taconic
Labs) were purchased at eight weeks of age and allowed to age further in our colony. Mice were
housed under standard conditions with a 12 h light/dark cycle. To measure glycemia, 1 mm of tail was
clipped and blood was tested with a glucometer and disposable test strips (Freestyle Lite, Alameda, CA
USA). Mice were considered hyperglycemic with a single blood glucose measurement of >150 mg/dL
for fasting blood glucose (FBG) or two consecutive measurements on different days of >300 mg/dL
for random blood glucose (RBG). For the diabetes prevention study, euglycemic NOD/MrkTac mice
(n = 20) at 12 weeks of age were split into two groups of 10, where one group was injected i.p. with
iBET-762 (30 mg/kg) dissolved in DMSO as stock solution of 50 mg/mL, which was further diluted
in saline to a concentration of 5 mg/mL. For the control group, an equivalent volume of vehicle (10%
DMSO in saline) solution was injected. For iBET and vehicle groups, the total volume injected was
between 150 and 200 µL. The treatment was carried out for 14 consecutive days. Following this, both
groups of mice were monitored for RBG. The RBG was measured once per week until they reached 30
weeks of age. At the end of the study, pancreata from the remaining euglycemic mice were harvested,
formaldehyde-fixed, and paraffin-embedded. For assessment of insulitis, 5 µm paraffin-embedded
sections from two vehicle and two iBET762-injected mice at 30 weeks of age from regions 50 µm apart
in the pancreas block were stained with hematoxylin and eosin. Insulitis was scored for three different
stages based on the level of infiltration of islet by immune cells, no insulitis, peri-insulitis (infiltration
at the periphery of the islets), and insulitis (infiltration within the islet) with n = 30 islets were scored
per mouse. For the iBET treatment of hyperglycemic mice, once the NOD/MrkTac were hyperglycemic,
as defined by RBG > 300 mg/dL, they were injected i.p. with iBET-762 (30 mg/kg) or vehicle for seven
consecutive days, and then sacrificed for pancreas dissection and histology.
4.2. Human Pancreas Sections and Islets
Human pancreas sections were obtained from the Network for Pancreatic Organ donors with
Diabetes (nPOD) program [22]. nPOD pancreas donors used in this study were nPOD Case IDs:
6279 (nondiabetic, 19-year-old male), 6397 (Glutamic acid decarboxylase autoantibody (GADA)
positive 21-year-old female), 6342 (Islet tyrosine phosphatase 2 autoantibody (IA-2A), Microinsulin
autoantibody (mIAA) double-positive, T1D 14-year-old female). Human islets were obtained from
the Integrated Islet Distribution Program (IIDP). Human islet preparations used in this study were
as follows: Donor #1: RRID:SAMN10784981, 45-year-old female, body mass index (BMI) = 35.7 and
Donor #2: RRID:SAMN11046361, 57-year-old male, BMI = 35.9.
4.3. Culture of Mouse Islets, Inhibitors and RNAi
Islets from NOD/ShiLtJ mice were isolated according to standard methods by collagenase digestion
through the bile duct. For collection of conditioned media (CM) from whole islets, after 1–2 h of resting
at 37 ◦C, NOD islets from n = 3 mice were separated into two equal pools per mouse, where one half was
cultured in vehicle (0.1% DMSO) and the other half was cultured in 5 µM iBET-762 (ApexBio, Houston,
TX, USA) in non-treated 96-well plates at 37 ◦C with 5% CO2 in 200 µL of serum-free mouse islet media
(RPMI 1640, 2 mM l-glutamine, 1X penicillin-streptomycin) for 24 h. Following the incubation, CM was
collected for analysis and islet DNA was either extracted immediately (Zymogen total genomic DNA
kit, Irvine, CA, USA) or islets were stored at −80 ◦C in genomic DNA lysis buffer to be extracted
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later. Collection of CM from CD45-depleted islet cell cultures was performed as previously [3], where
islets were pooled from five or ten 14-week-old NOD mice, depleted of CD45+ immune cells using
metal-assisted cell sorting (BioLegend, San Diego, CA, USA) and plated at 60,000–100,000 cells per
well (equal numbers per well) in three biological replicates per group in mouse serum-free islet media
containing vehicle (0.1% DMSO) or 5 µM iBET-762 for 24 h. Following incubation, the CM was collected
for paracrine assays. For qRT-PCR of CD45-depleted islet cultures, cells were incubated with iBET-762
in media containing 10% Fetal Bovine Serum (FBS) (rather than in serum-free media). For RNAi,
after recovery of NOD islets for 18 h in serum-containing islet media (RPMI 1640, 2 mM l-glutamine,
1X penicillin-streptomycin, 10% FBS), 20 islets per well (n = 3 biological replicates per group) were
transfected with control (non-targeting #2) siRNA or mouse Brd4 SMARTpool siRNA (Dharmacon GE
Life Sciences, Lafeyette, CO, USA) at 100 nM each with lipofectamine 3000 according to the product
instructions. Islets were cultured for an additional 72 h and then harvested for RNA extraction. THP-1
human monocytic leukemia cells (purchased from ATCC, Gaithersburg, MD, USA) were cultured in
RPMI-1640, 10% FBS, and 1X penicillin–streptomycin at 37 ◦C with 5% CO2.
4.4. Culture of Human Islets and Inhibitors
Human islets from IIDP were cultured as previously [3] in RPMI-1640 containing 10% FBS, 5.5 mM
glucose, and 1X antibiotic-antimycotic (Gibco, Grand Island, NY, USA). Islets were rested for 24 h in
culture prior to inducing DNA damage with 50 µM bleomycin. Forty-eight hours later, bleomycin
was removed and fresh media was added, and islets were then cultured with vehicle (0.1% DMSO)
or 5 µM iBET-762. Five days later, islets were transferred into serum-free media for the collection of
conditioned media (CM). After 24 h, CM was collected for luminex assays and islets were harvested
for RNA extraction and qRT-PCR.
4.5. Immunohistochemistry and Quantification
Immunohistochemistry of formaldehyde-fixed paraffin-embedded pancreas sections was
performed as described [23]. Five micron tissue sections were rehydrated with xylene and graded
ethanol washes, soaked in 1% H2O2 for 10 min, and subjected to heat-mediated antigen retrieval with
sodium citrate pH 6.0 for 7.5 min at 100% and 14 min at 50% power in a 1250 W microwave. Sections
were cooled to room temperature with tap water and then permeabilized with TBS containing 0.1%
Triton-x-100 for five min. Sections were blocked with 2% normal donkey serum in protein block buffer
(Dako) for 15 min and then incubated overnight at 4 ◦C with primary antibodies diluted in DAKO
antibody diluent: anti-insulin (DAKO, 1:1000), anti-BRD4 (Bethyl laboratories, 1:10,000, Montgomery,
TX, USA), anti-IL-6 (Novus Biologicals 1:300, Centennial, CO, USA), and anti-Flnb (Novus Biologicals,
1:500, Centennial, CO, USA) [3]. Fluorescein isothiocyanate (FITC) or Cy3-conjugated secondary
antibodies (Jackson Immunoresearch, West Grove, PA, USA) were used to detect primary antibodies
and sections were counterstained with Vectashield with DAPI (Vector Labs, Burlingame, CA, USA).
Images were taken on a Zeiss Axioscope2 wide-field fluorescence microscope (Carl Zeiss Vision Inc,
San Diego, CA, USA) with Axiovision software. IL-6 was quantified in beta cells from recent onset
diabetic NOD mice ranging in ages from 12 to 19 weeks that were vehicle treated (n = 3) or iBET-762
treated (n = 3), with three pairs of age-matched mice among the groups (12–14 weeks, 16 weeks, 17–19
weeks). Because the mice were diabetic in this study, they had widely varying numbers of remaining
islets and remaining beta cells per islet. To account for these differences, frequencies of IL-6+ beta cells
were calculated from a similar number of total beta cells scored from the mice. A total of n = 20 islets
with 735 beta cells was scored from vehicle mice, and n = 16 islets with 891 beta cells were scored in
iBET-762 mice, taking sections throughout the pancreas from mice in both groups. Residual islets
containing fewer than 10 beta cells were not scored.
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4.6. THP-1 Chemotaxis Assay
Chemotaxis assays were performed as previously described using transwell inserts with 5 µm
polycarbonate membranes [3]. Briefly, 1 × 105 THP-1 cells were seeded into 150 µL of control media
(serum-free THP1 media: RPMI 1640, 2 mM l-glutamine, 1% penicillin-streptomycin) in the upper
chamber and 150 µL of control media alone or islet CM (with vehicle or iBET-762 treatment) was added
to the lower chamber. Cells were allowed to migrate for 5–6 h at 37 ◦C, and then the inserts were
removed and the cells in the lower chamber were counted. The control media in the lower chamber
was used to determine background levels of migration and the fold-change relative to the control
media was used to determine relative chemotaxis in the other samples.
4.7. Paracrine Senescence Assays
Paracrine senescence assays were performed as previously described [3]. NOD islets isolated
from three-week old mice were cultured for four days with CM from islets of 14 to 15 weeks NOD mice
depleted of CD45+ cells that were treated with vehicle or iBET-762. After culture period the three-week
NOD islets were harvested for RNA and qRT-PCR.
4.8. ChIP and qPCR
Crosslinked ChIP was performed with the MicroChIP kit (Diagenode, Denville, NJ, USA)
according to the product instructions. For H3K27ac ChIP, the islets were prepared from 13–14-week-old
NOD/MrkTac or NOD/ShiLtJ mice and rested 18 h in mouse islet media. The following day, all the
islets from one mouse each were dissociated into single cell suspension using a nonenzymatic buffer
reagent (Gibco) and counted with trypan blue. Approximately 2–5 × 105 cells were crosslinked with
1% formaldehyde for 10 min at room temperature, quenched with glycine, and then sonicated with
the Diagenode Bioruptor to generate ~200–600 bp fragments. ChIP was performed with 1 µg of
anti-H3K27ac (Abcam ab4729, Cambridge, MA, USA) or total rabbit IgG (Sigma-Aldrich, St. Louis,
MO, USA) and incubated overnight at 4 ◦C, followed by capture on protein A dynabeads. Crosslinked
ChIP of BRD4 from NOD mouse islets was performed using the True MicroChIP kit (Diagenode) and
the same procedure was followed for preparing islets. Then, instead of resting overnight, the islets from
five NOD mice were divided into two pools, where one set was incubated with vehicle (0.1% DMSO)
and the other incubated with 5 µM iBET-762 for 18 h (n = 2 biological replicates per group). Islets were
then dissociated, crosslinked, and sonicated as described above. ChIP was performed using 1 µg of
anti-BRD4 (Bethyl labs A301-985) or total rabbit IgG (Sigma-Aldrich). Ten percent input fractions
from all were saved and DNA extracted in parallel with the ChIP samples for qPCR normalization.
qPCR using SYBR green was performed using the following forward and reverse primers
(5′-3′): Mmp2 enhancer AACATGCAAGGGAGATCAGC and 5′GGGCTATGAAATGCCAGAAA;
Mmp2 distal GCTGGTCCCACAGTGAAGTT and GGACACAGCGCAACTGAATA; Il6
promoter TGTGGGATTTTCCCATGA and TGCCTTCACTTACTTGCAGAGA; Il6 distal
GAGAGAGGCAAGCACAGAAA and CCGAGCTGGTTGGTGATAAG. ChIP enrichment was
calculated using the percent input method.
4.9. Quantitative Reverse-Transcription PCR
Total RNA was extracted from mouse or human islets cultured as described above and treated with
DNAse I with the Zymogen RNA extraction micro kit (Zymogen, Irvine, CA, USA) according to the
product instructions. RNA was converted into cDNA using oligo(dT) primer and the SuperScript IV kit
(Invitrogen, Carlsbad, CA, USA) or the qScript kit (QuantaBio, Beverly, MA, USA). qPCR was performed
with the ABI 7900HT system and SDS 2.4 software and target gene primers used previously, and
relative quantification was performed with the ∆∆CT method using RQ manager 1.2.1, and expression
values were normalized to mouse Ppia or human PPIA as a housekeeping gene [3]. Primer sequences
for mouse Il6; Ppia; and human CDKN1A, CDKN2A (p16), and PPIA were as previously described [3].
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Newly designed forward and reverse primer sequences used in this study were as follows (forward
and reverse, 5′-3′): Flnb: AACCAGAACTGGAAGATGG and ATGGCTTCTCGGGCATTATC;
Mmp2: CCCCGATCTACACCTACACC and GGAGTGACAGGTCCCAGTGT; Igfbp4:
ATCGAAGCCATCCAGGAAAG and CAGGGGTTGAAGCTGTTGTT; and Brd4:
TTCAGCACCTCACTTCGACC and CTGGTGTTTTTGGCTCCTGC.
4.10. Luminex Assays
Luminex assays were performed on 50 µL of islet CM, according to the product instructions
using either the custom human panel (R&D systems, Minneapolis, MN, USA) reported previously [3]
or using a custom mouse panel (R&D systems) including the following: IL-6, Mmp12, Mmp3, and
Igfbp3. Analyte concentrations were determined from standard curves of purified proteins in each
assay provided in the kits. For mouse islet secretion assays involving inhibitor treatments, islets were
saved for DNA extraction to normalize concentrations to DNA content and data were pg of secreted
factor per µg DNA and expressed as a fold-change relative to the pool of vehicle-treated islets from the
same mouse (n = 3 mice). For human islet secretion assays, data were normalized to RNA content and
reported as pg secreted factor per µg RNA.
4.11. Statistics
The number of biological replicates, number of mice used, and repeated experiments are indicated
in the figure legends. Statistical analyses were performed where experiments were carried out using
three or more biological replicates or independent experiments using unpaired one-way ANOVA
for groups of three or with unpaired two-tailed t-tests for groups of two. Log-rank test was used to
compare diabetes incidence curves. The results were considered significant at p < 0.05. Statistics were
computed using GraphPad prism v6.0.
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Abbreviations
BET Bromodomain ExtraTerminal domain
NOD Nonobese diabetic
qRT-PCR Quantitative reverse transcription polymerase chain reaction
ChIP Chromatin immunoprecipitation
DMSO Dimethyl sulfoxide
DDR DNA damage response
SASP Senescence-associated secretory phenotype
ATM Ataxia Telangiectasia mutated
NF-κB Nuclear Factor kappa B
PARP1 Poly-(ADP) ribose polymerase 1
macroH2A1 Macro Histone H2A1
Bcl-2 B cell lymphoma 2
HMGB2 High mobility group protein B2
CEBPβ CAAT enhancer binding protein beta
MLL1 Mixed lineage leukemia 1
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Mitf Melanocyte inducing transcription factor
H3K27ac Histone H3 Lysine 27 acetylation
dbSUPER Database of Superenhancers
BRD4 Bromodomain-containing protein 4
siRNA Small interfering RNA
IL-6 Interleukin 6
Flnb Filamin B
Mmp2 Matrix metalloprotease 2
Igfbp4 Insulin-like growth factor binding protein 4
Ppia Peptidyl prolyl isomerase A
Cdkn1a Cyclin dependent kinase inhibitor 1A
Cdkn2a Cyclin dependent kinase inhibitor 2A
CD45 Cluster of differentiation 45
FITC Fluorescein isothiocyanate
T1D Type 1 Diabetes
Cxcl1 CXC Chemokine ligand 1
IL-8 Interleukin 8
References
1. Bluestone, J.A.; Herold, K.; Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes.
Nature 2010, 464, 1293–1300. [CrossRef]
2. Christoffersson, G.; Rodriguez-Calvo, T.; von Herrath, M. Recent advances in understanding Type 1 Diabetes.
F1000Research 2016, 5, 1–8. [CrossRef] [PubMed]
3. Thompson, P.J.; Shah, A.; Ntranos, V.; Van Gool, F.; Atkinson, M.; Bhushan, A. Targeted Elimination of
Senescent Beta Cells Prevents Type 1 Diabetes. Cell Metab. 2019, 29, 1045–1060. [CrossRef] [PubMed]
4. Coppé, J.-P.; Patil, C.K.; Rodier, F.; Sun, Y.; Muñoz, D.P.; Goldstein, J.; Nelson, P.S.; Desprez, P.-Y.; Campisi, J.
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the
p53 tumor suppressor. PLoS Biol. 2008, 6, 2853–2868. [CrossRef] [PubMed]
5. Kuilman, T.; Michaloglou, C.; Vredeveld, L.C.W.; Douma, S.; van Doorn, R.; Desmet, C.J.; Aarden, L.A.;
Mooi, W.J.; Peeper, D.S. Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory
Network. Cell 2008, 133, 1019–1031. [CrossRef] [PubMed]
6. Özcan, S.; Alessio, N.; Acar, M.B.; Mert, E.; Omerli, F.; Peluso, G.; Galderisi, U. Unbiased analysis of
senescence associated secretory phenotype (SASP) to identify common components following different
genotoxic stresses. Aging (Albany. NY). 2016, 8, 1316–1329. [CrossRef] [PubMed]
7. Freund, A.; Patil, C.K.; Campisi, J. p38MAPK is a novel DNA damage response-independent regulator of the
senescence-associated secretory phenotype. EMBO J. 2011, 30, 1536–1548. [CrossRef]
8. Tasdemir, N.; Banito, A.; Roe, J.-S.; Alonso-Curbelo, D.; Camiolo, M.; Tschaharganeh, D.F.; Huang, C.-H.;
Aksoy, O.; Bolden, J.E.; Chen, C.-C.; et al. BRD4 Connects Enhancer Remodeling to Senescence Immune
Surveillance. Cancer Discov. 2016, 6, 612–629. [CrossRef]
9. Capell, B.C.; Drake, A.M.; Zhu, J.; Shah, P.P.; Dou, Z.; Dorsey, J.; Simola, D.F.; Donahue, G.; Sammons, M.;
Rai, T.S.; et al. MLL1 is essential for the senescence- associated secretory phenotype. Genes Dev. 2016, 30,
321–336. [CrossRef]
10. Aird, K.M.; Iwasaki, O.; Kossenkov, A.V.; Tanizawa, H.; Fatkhutdinov, N.; Bitler, B.G.; Le, L.; Alicea, G.;
Yang, T.L.; Johnson, F.B.; et al. HMGB2 orchestrates the chromatin landscape of senescence-associated
secretory phenotype gene loci. J. Cell Biol. 2016, 215, 325–334. [CrossRef]
11. Rodier, F.; Coppé, J.P.; Patil, C.K.; Hoeijmakers, W.A.M.; Muñoz, D.P.; Raza, S.R.; Freund, A.; Campeau, E.;
Davalos, A.R.; Campisi, J. Persistent DNA damage signalling triggers senescence-associated inflammatory
cytokine secretion. Nat. Cell Biol. 2009, 11, 973–979. [CrossRef] [PubMed]
12. Chen, H.; Ruiz, P.D.; McKimpson, W.M.; Novikov, L.; Kitsis, R.N.; Gamble, M.J. MacroH2A1 and ATM Play
Opposing Roles in Paracrine Senescence and the Senescence-Associated Secretory Phenotype. Mol. Cell 2015,
59, 719–731. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 4776 13 of 13
13. Ohanna, M.; Giuliano, S.; Bonet, C.; Imbert, V.; Hofman, V.; Zangari, J.; Bille, K.; Robert, C.; Bressac-de
Paillerets, B.; Hofman, P.; et al. Senescent cells develop a PARP-1 and nuclear factor- k B-associated secretome
(PNAS). Genes Dev. 2011, 25, 1245–1261. [CrossRef] [PubMed]
14. Kirkland, J.L.; Tchkonia, T. Cellular Senescence: A Translational Perspective. EBioMedicine 2017, 21, 21–28.
[CrossRef] [PubMed]
15. Sharpless, N.E.; Sherr, C.J. Forging a signature of in vivo senescence. Nat. Rev. Cancer 2015, 15, 397–408.
[CrossRef] [PubMed]
16. Pearson, J.A.; Wong, F.S.; Wen, L. The importance of the Non Obese Diabetic (NOD) mouse model in
autoimmune diabetes. J. Autoimmun. 2016, 66, 76–88. [CrossRef] [PubMed]
17. Khan, A.; Zhang, X. DbSUPER: A database of Super-enhancers in mouse and human genome. Nucleic
Acids Res. 2016, 44, D164–D171. [CrossRef]
18. Nicodeme, E.; Jeffrey, K.L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.; Chandwani, R.; Marazzi, I.;
Wilson, P.; Coste, H.; et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468,
1119–1123. [CrossRef]
19. Fu, W.; Farache, J.; Clardy, S.M.; Hattori, K.; Mander, P.; Lee, K.; Rioja, I.; Weissleder, R.; Prinjha, R.K.;
Benoist, C.; et al. Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and
Beta cells. Elife 2014, 3, e04631. [CrossRef]
20. Ferri, E.; Petosa, C.; McKenna, C.E. Bromodomains: Structure, function and pharmacology of inhibition.
Biochem. Pharmacol. 2016, 106, 1–18. [CrossRef]
21. Malaquin, N.; Martinez, A.; Rodier, F. Keeping the senescence secretome under control: Molecular reins on
the senescence-associated secretory phenotype. Exp. Gerontol. 2016, 82, 39–49. [CrossRef] [PubMed]
22. Campbell-Thompson, M. Organ donor specimens: What can they tell us about type 1 diabetes? Pediatr.
Diabetes 2015, 16, 320–330. [CrossRef] [PubMed]
23. Dhawan, S.; Tschen, S.; Zeng, C.; Guo, T.; Hebrok, M.; Matveyenko, A.; Bhushan, A. DNA methylation directs
functional maturation of pancreatic β cells. J. Clin. Investig. 2015, 125, 2851–2860. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
